Prognostic impact of INK4A deletion in Ewing sarcoma

The primary genetic alteration in > 95% of Ewing sarcomas (ES) is a specific fusion of EWS with FLI1 or ERG. Secondary genetic alterations possibly involved in progression of ES are not well understood. A recent study found loss of the negative cell cycle regulator gene INK4A in 8 of 27 ES samples (30%). To confirm these findings and evaluate their prognostic significance, the authors studied INK4A deletion in 41 ES samples from 39 patients.

[1]  M. Ladanyi,et al.  Prognostic impact of P53 status in Ewing sarcoma , 2000, Cancer.

[2]  M. Ladanyi,et al.  Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications. , 2000, The American journal of pathology.

[3]  P. Sorensen,et al.  EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Ladanyi,et al.  Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. , 1999, Cancer research.

[5]  P. Ambros,et al.  Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors , 1999, Genes, chromosomes & cancer.

[6]  R. DePinho,et al.  The INK4A/ARF locus and its two gene products. , 1999, Current opinion in genetics & development.

[7]  F. Mertens,et al.  Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome? , 1999, Medical and pediatric oncology.

[8]  G. Wei,et al.  CDK4 gene amplification in osteosarcoma: Reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons , 1999, International journal of cancer.

[9]  A. Huvos,et al.  The Histological Response to Chemotherapy as a Predictor of the Oncological Outcome of Operative Treatment of Ewing Sarcoma* , 1998, The Journal of bone and joint surgery. American volume.

[10]  W. Gerald,et al.  EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[12]  H. Kovar Progress in the Molecular Biology of Ewing Tumors , 1998, Sarcoma.

[13]  R. Perez-soler,et al.  Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. , 1998, International journal of oncology.

[14]  F. Sigaux,et al.  Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. , 1998, Blood.

[15]  J. Fletcher,et al.  Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. , 1998, Cancer genetics and cytogenetics.

[16]  F. Perler,et al.  Protein Splicing of Inteins and Hedgehog Autoproteolysis: Structure, Function, and Evolution , 1998, Cell.

[17]  R. Kratzke,et al.  Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  H. Kovar,et al.  Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors , 1997, Oncogene.

[19]  S. Ferrari,et al.  Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Quelle,et al.  Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Siebenrock,et al.  Comparison of soft tissue Ewing's sarcoma and peripheral neuroectodermal tumor. , 1996, Clinical orthopaedics and related research.

[22]  A. Llombart‐Bosch,et al.  Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. , 1996, Seminars in diagnostic pathology.

[23]  O. Delattre,et al.  Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Koeffler,et al.  Alterations of the p15, p16,and p18 genes in osteosarcoma. , 1996, Cancer genetics and cytogenetics.

[25]  W. Gerald,et al.  Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Hovig,et al.  Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1. , 1995, British Journal of Cancer.

[27]  W. Gerald,et al.  MDM2 and CDK4 gene amplification in Ewing's sarcoma , 1995, The Journal of pathology.

[28]  J. Pelletier,et al.  Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. , 1995, Cancer research.

[29]  C. Larsson,et al.  The human NOTCH1, 2, and 3 genes are located at chromosome positions 9q34, 1p13-p11, and 19p13.2-p13.1 in regions of neoplasia-associated translocation. , 1994, Genomics.

[30]  T. Triche,et al.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.

[31]  N. Nowak,et al.  Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations , 1994, Nature Genetics.

[32]  G. Thomas,et al.  p53 mutations in human tumors with chimeric EWS/FLI/1 genes , 1994, International journal of cancer.

[33]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[34]  P. Sorensen,et al.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG , 1994, Nature Genetics.

[35]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[36]  R. Hanada,et al.  Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. , 1993, Cancer research.

[37]  H. Kovar,et al.  Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. , 1993, Oncogene.

[38]  A. Aurias,et al.  Chromosomes in Ewing's sarcoma. II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). , 1988, Cancer genetics and cytogenetics.

[39]  P. Pynsent,et al.  Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis , 1999, British Journal of Cancer.

[40]  O. Myklebost,et al.  Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. , 1997, British Journal of Cancer.

[41]  D. Louis,et al.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.

[42]  T. Triche,et al.  Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis? , 1995, European journal of cancer.